T
Tennor Therapeutics
Specializes in research and development of new drugs for the treatment of digestive diseases
About Tennor Therapeutics
TenNor Therapeutics is a biotechnology company specializing in the development of innovative antibiotic treatments for complex infections. The company primarily serves healthcare providers and medical institutions, focusing on addressing unmet medical needs in the treatment of anaerobic pathogens and periprosthetic joint infections. Operating in the global pharmaceutical market, TenNor leverages advanced research and development to create novel antibiotic conjugates, such as oxazolidinone nitroimidazole, which have shown synergistic activity against difficult-to-treat infections. The business model revolves around the development and commercialization of these specialized antibiotics, generating revenue through product sales, licensing agreements, and collaborations with other pharmaceutical companies. TenNor's strategic partnerships with renowned institutions like the Mayo Clinic further bolster its research capabilities and market reach.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Suzhou Shi, China
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 59.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Tennor Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | May 2026 | $67M | — | Undisclosed | ↗ |
| SERIES EOther financing | Oct 2024 | $42M | $169M | AMR Action Fund · Zhongshan Venture Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Tennor Therapeutics is 150 monthly website visits, down 92.1% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
NLVC
Relativity Healthcare Partners
WuXi Healthcare Ventures- FBFrontline BioVentures
Oriza Ventures
Series B and later10 investors entered at this stage
- SGShenZhen GTJA Investment Group
Yanchuang Capital- BHBison Capital Financial Holdings
- GCGalaxy Capital
Oriza Holdings- ZCZhongda Venture Capital
Broad Resources- BCBeijing Venture Capital
AMR Action Fund- ZCZhongshan Venture Capital
Other known investors1 additional known investor
6 Dimensions Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tennor Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tennor Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.